Stock 2186 LUYE PHARMA GROUP LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Luye Pharma Group Ltd.

Equities

2186

BMG570071099

Pharmaceuticals

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:20 2024-04-26 am EDT 		5-day change 1st Jan Change
2.72 HKD +0.74% Intraday chart for Luye Pharma Group Ltd. +4.21% -27.08%
Mar. 27 Luye Pharma Group Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Mar. 07 Luye Pharma Group Announces the Launch of Its Innovative Drug Zepzelca® (Lurbinectedin) for the Treatment of SCLC in Both Hong Kong and Macao CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Capitalization 1 15,649 17,061 9,872 10,273 11,474 9,471 9,471 -
Enterprise Value (EV) 1 20,114 19,939 15,881 16,937 15,546 12,753 12,418 12,054
P/E ratio 11.8 x 11.4 x 13.7 x -74.4 x 18.6 x 23.7 x 15.6 x 11.8 x
Yield 2.09% 2.17% - - - - - -
Capitalization / Revenue 3.02 x 2.68 x 1.78 x 1.98 x 1.92 x 2.08 x 1.4 x 1.22 x
EV / Revenue 3.89 x 3.14 x 2.87 x 3.26 x 2.6 x 2.08 x 1.83 x 1.55 x
EV / EBITDA 11.6 x 7.81 x 8.46 x 18.7 x 8.58 x 6.14 x 6.87 x 6.59 x
EV / FCF 63,366,390 x 25,743,540 x 46,621,206 x -45,307,565 x 31,699,228 x - - -
FCF Yield 0% 0% 0% -0% 0% - - -
Price to Book 1.97 x 1.81 x 1.23 x 1.18 x 1.11 x 0.77 x 0.73 x 0.69 x
Nbr of stocks (in thousands) 3,269,965 3,268,965 3,248,965 3,541,372 3,549,671 3,761,671 3,761,671 -
Reference price 2 4.786 5.219 3.038 2.901 3.232 2.518 2.518 2.518
Announcement Date 3/28/19 3/26/20 3/31/21 3/29/22 3/29/23 3/27/24 - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Net sales 1 5,173 6,358 5,540 5,200 5,982 6,143 6,789 7,782
EBITDA 1 1,733 2,553 1,877 906.9 1,813 2,077 1,809 1,830
EBIT 1 1,422 1,729 961.2 -6.49 747.6 872.9 1,065 1,235
Operating Margin 27.5% 27.2% 17.35% -0.12% 12.5% 14.21% 15.69% 15.87%
Earnings before Tax (EBT) 1 1,473 1,772 942.2 -74.56 669.8 700.1 767.3 962.9
Net income 1 1,303 1,469 706.6 -134.4 604.8 532.6 657.8 930.8
Net margin 25.19% 23.1% 12.76% -2.58% 10.11% 8.67% 9.69% 11.96%
EPS 2 0.4045 0.4584 0.2212 -0.0390 0.1738 0.1429 0.1614 0.2137
Free Cash Flow 317.4 774.5 340.6 -373.8 490.4 - - -
FCF margin 6.14% 12.18% 6.15% -7.19% 8.2% - - -
FCF Conversion (EBITDA) 18.31% 30.34% 18.15% - 27.05% - - -
FCF Conversion (Net income) 24.35% 52.74% 48.21% - 81.09% - - -
Dividend per Share 2 0.1000 0.1130 - - - - - -
Announcement Date 3/28/19 3/26/20 3/31/21 3/29/22 3/29/23 3/27/24 - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2019 S1 2019 S2 2020 S1 2020 S2 2021 S1 2021 S2 2022 S1 2022 S2 2023 S1 2023 S2
Net sales 1 3,131 3,227 2,962 2,577 2,952 2,249 2,851 3,131 2,904 3,239
EBITDA - - - - - - - - - -
EBIT 1 - - - - - 521.8 589.5 300.6 - -294.8
Operating Margin - - - - - 23.2% 20.68% 9.6% - -9.1%
Earnings before Tax (EBT) - - - - - - - - - -
Net income - - - - - - - - - -
Net margin - - - - - - - - - -
EPS 2 0.2382 0.2202 0.1686 0.0526 0.1129 -0.1519 0.0854 0.0884 0.0406 0.1023
Dividend per Share - - - - - - - - - -
Announcement Date 8/28/19 3/26/20 8/27/20 3/31/21 8/29/21 3/29/22 8/29/22 3/29/23 8/29/23 3/27/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Net Debt 1 4,465 2,878 6,009 6,665 4,072 3,669 2,947 2,583
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 2.576 x 1.127 x 3.201 x 7.349 x 2.246 x 2.496 x 1.629 x 1.411 x
Free Cash Flow 317 775 341 -374 490 - - -
ROE (net income / shareholders' equity) 17.9% 17.2% 10.9% -1.64% 6.48% 6.1% 4.73% 5.86%
ROA (Net income/ Total Assets) 9.21% 7.97% 4.56% 2.03% - - - -
Assets 1 14,150 18,426 15,497 -6,614 - - - -
Book Value Per Share 2 2.430 2.880 2.480 2.460 2.920 3.290 3.460 3.670
Cash Flow per Share 0.3200 0.5400 0.3200 0.0500 0.4800 - - -
Capex 728 970 693 556 1,163 - - -
Capex / Sales 14.08% 15.26% 12.51% 10.7% 19.45% - - -
Announcement Date 3/28/19 3/26/20 3/31/21 3/29/22 3/29/23 3/27/24 - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Luye Pharma Group Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
4
Last Close Price
2.518 CNY
Average target price
2.785 CNY
Spread / Average Target
+10.60%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
LUYE PHARMA GROUP LTD. Stock Luye Pharma Group Ltd.
-27.08% 1.31B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 2186 Stock
  4. Financials Luye Pharma Group Ltd.